NCT04684147 - Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 24, 2020

Primary Completion Date

September 22, 2022

Study Completion Date

December 31, 2026

Conditions

Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

single dose of CNCT19

Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide

Trial Locations (11)

100000

RECRUITING

Beijing Boren Hospital, Beijing

200000

RECRUITING

Tongji Hospital of Tongji University, Shanghai

221006

RECRUITING

The affiliated hospital of Xuzhou medical university, Xuzhou

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

310000

RECRUITING

The First Affiliated Hospital, Zhejiang University school of Medicine, Hangzhou

400000

RECRUITING

Xinqiao Hospital of TMMU, Chongqing

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

610000

RECRUITING

West China Hospital，Sichuan University, Chengdu

Unknown

RECRUITING

Nanfang Hospital, Guangzhou

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

065200

NOT_YET_RECRUITING

Yanda hospital, Hebei medical university, Sanhe